STAT October 13, 2024
Jason Mast

The company, like some others, is developing technologies to insert full-length genes into patients

SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda
The financial burden of drug shortages: 7 study takeaways
What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices
Q&A: Generating data from neurons to teach AI the rules of the brain

Share This Article